APA (7th ed.) Citation

Michaeli, C. T., Jürges, H., & Michaeli, D. (2023). FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: Cross sectional analysis. The BMJ, 381, . https://doi.org/10.1136/bmj-2022-073242

Chicago Style (17th ed.) Citation

Michaeli, Christoph T., Hendrik Jürges, and Daniel Michaeli. "FDA Approval, Clinical Trial Evidence, Efficacy, Epidemiology, and Price for Non-orphan and Ultra-rare, Rare, and Common Orphan Cancer Drug Indications: Cross Sectional Analysis." The BMJ 381 (2023). https://doi.org/10.1136/bmj-2022-073242.

MLA (9th ed.) Citation

Michaeli, Christoph T., et al. "FDA Approval, Clinical Trial Evidence, Efficacy, Epidemiology, and Price for Non-orphan and Ultra-rare, Rare, and Common Orphan Cancer Drug Indications: Cross Sectional Analysis." The BMJ, vol. 381, 2023, https://doi.org/10.1136/bmj-2022-073242.